Volume 126, Issue 9 pp. 2191-2198
Epidemiology

Relationship between dietary and supplemental intake of folate, methionine, vitamin B6 and folate receptor α expression in ovarian tumors

Joanne Kotsopoulos

Corresponding Author

Joanne Kotsopoulos

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Fax: 617-525-2008

Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, USASearch for more papers by this author
Jonathan L. Hecht

Jonathan L. Hecht

Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

Search for more papers by this author
Jonathan D. Marotti

Jonathan D. Marotti

Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

Search for more papers by this author
Linda E. Kelemen

Linda E. Kelemen

Department of Population Health Research, Alberta Cancer Board, Calgary, Alberta

Search for more papers by this author
Shelley S. Tworoger

Shelley S. Tworoger

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts

Search for more papers by this author
First published: 07 July 2009
Citations: 12

Abstract

Because folate receptor α (FRα) is frequently over-expressed in epithelial ovarian tumors, we hypothesized that its association with folate may differ by FRα expression or by the timing of intake. We examined the association between folate and other cofactors in 152 ovarian cancers evaluated for FRα expression from the Nurses' Health Study. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression. FRα expression was higher in serous invasive and advanced stage ovarian tumors. Recent dietary folate intake ≥ 300 μg/day compared to < 300 μg/day was associated with decreased risk of developing ovarian cancer (OR = 0.62; 95%CI 0.40–0.96). There was suggestion of an increased risk with total folate (dietary and supplemental) (OR=1.42; 95%CI 0.94–2.14 for past and OR = 1.53; 95%CI 0.99–2.37 for recent intake). These results did not vary by FRα status of the tumor. Methyl group score, a marker of high dietary folate and methionine intake but low alcohol consumption, was inversely associated with risk of ovarian cancer (OR = 0.44; 95%CI 0.23–0.84 for past and OR=0.46; 95%CI 0.24–0.88 for recent intake). There were no clear individual associations between methionine, vitamin B6, or multivitamin use and ovarian cancer risk overall or by FRα tumor status. Our data do not support the hypothesis that the relationship between factors involved in one-carbon metabolism and ovarian cancer risk differs by FRα status of the tumor.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.